For research and educational purposes only. Not intended for human consumption.
Wolverine Stack
Well Researched- •2021 clinical study: 87.5% knee pain improvement
- •Synergistic actin regulation mechanism detailed
- •Enhanced angiogenesis and cell migration data
BPC-157 + TB-500 | Tissue Repair & Recovery Protocol
Overview
What is Wolverine Stack?
The Wolverine Stack combines BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) for enhanced tissue repair and recovery. Named after the Marvel character known for regenerative abilities, this combination targets complementary healing pathways: BPC-157 increases actin production and promotes angiogenesis via nitric oxide modulation, while TB-500 binds actin to facilitate cell migration and reduce scarring. A 2021 clinical study showed 87.5% of patients experienced knee pain relief. Banned by WADA
Key Benefits
Combines complementary healing mechanisms: BPC-157 promotes angiogenesis and reduces inflammation while TB-500 enhances cell migration and reduces scarring. Clinical study showed 87.5% improvement in knee pain patients.
Mechanism of Action
BPC-157 increases actin production at gene level and modulates nitric oxide for vascular effects. TB-500 is an actin-binding protein that sequesters actin for cell migration. Together they enhance fibroblast and immune cell movement to injury sites through synergistic actin regulation.
Molecular Information
Pharmacokinetics
Research Indications
Tendon & Ligament Healing
Both peptides accelerate tendon and ligament repair. BPC-157 improved Achilles tendon healing in animal models.
Muscle Injury Recovery
BPC-157 enhanced muscle regeneration. TB-500 promotes cell migration for muscle repair.
Joint Pain & Cartilage
Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4 combination.
Research Protocols
Disclaimer: Research protocol only. Both peptides are banned by WADA. Contraindicated with cancer history.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Recovery | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC daily, TB-500 Mon/Thu | Subcutaneous |
| Intensive Injury Recovery | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC daily, TB-500 twice weekly | SubQ near injury site |
| Maintenance/Prevention | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC daily, TB-500 weekly | Subcutaneous |
Timing: BPC-157 has short half-life so twice daily dosing maintains levels. TB-500 allows twice weekly dosing. Can inject same time but use separate sites.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Reconstitute each peptide separately
BPC-157: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
TB-500: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
Inject slowly down vial wall, swirl gently - never shake
Do NOT mix peptides in same syringe unless pre-made blend
Use separate injection sites if administering same day
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White lyophilized powder
Both vials should contain white or off-white fluffy powder cake.
Clear after reconstitution
Both solutions should be crystal clear with no particles.
Certificate of Analysis
HPLC purity testing (>98%) and mass spec verification for both.
Collapsed or discolored
Yellowed or stuck powder may be heat-degraded - do not use.
What to Expect
- •Week 1-2: Reduction in acute inflammation and pain at injury sites
- •Week 2-4: Improved recovery between workouts, reduced soreness
- •Week 4-6: Significant improvement in chronic injuries, joint comfort
- •Week 6-8: Optimal healing effects, structural improvements
- •Post-cycle: Benefits may persist as healed tissue maintains integrity
Side Effects & Safety
Side Effects
- •Not FDA approved - research chemical only
- •Contraindicated with ANY history of cancer
- •Banned by WADA and major sports organizations
- •Limited human safety data - most research preclinical
- •Do not combine with chemotherapy
- •Monitor for unusual tissue growth
When to Stop
- •Any unusual growths or tissue changes
- •Signs of adverse effects
- •As directed by healthcare provider
References
3 StudiesBPC-157 Systematic Review (2025)
36 articles | Orthopedic focus | Preclinical improvements in muscle, tendon, ligament, fracture
Enhanced GH receptor expression and angiogenesis with reduced inflammatory cytokines.
BPC-157 + TB4 Knee Pain Study (2021)
Human | 16 patients | Intra-articular | 87.5% experienced knee pain relief
First published study combining BPC-157 and TB4. BPC-157 alone: 91.6% improvement. Combination: 75% improvement.
View StudyThymosin β4 Wound Healing Phase 2 (2012)
Human | Stasis and pressure ulcers | Accelerated healing by ~1 month
TB4 accelerated wound healing in patients who responded to treatment.
View StudyQuick Start Guide
Research Disclaimer
Wolverine Stack is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Wolverine Stack must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Wolverine Stack for any purpose. Consult qualified professionals for any research applications.